PROKIDNEY CORP.

For the period ended Sep 30, 2025. Filed Nov 10, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 10, 2025

PROK$1.11-3.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

Condensed Consolidated Statements of Operations - Unaudited

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Revenue	$217	$–	$668	$–
Operating expenses
Research and development	26,821	31,250	79,966	87,887
General and administrative	11,935	17,723	40,338	44,218
Total operating expenses	38,756	48,973	120,304	132,105
Operating loss	(38,539)	(48,973)	(119,636)	(132,105)
Other income (expense):
Interest income	3,258	5,580	10,878	14,960
Interest expense	(2)	(2)	(3)	(7)
Net loss before income taxes	(35,283)	(43,395)	(108,761)	(117,152)
Income tax expense (benefit)	560	(2,342)	1,999	(2,300)
Net loss before noncontrolling interest	(35,843)	(41,053)	(110,760)	(114,852)
Net loss attributable to noncontrolling interest	(19,374)	(23,143)	(61,005)	(74,944)
Net loss available to Class A common stockholders	$(16,469)	$(17,910)	$(49,755)	$(39,908)
Weighted average shares of Class A common stock outstanding:
Basic and diluted	134,992,796	126,173,463	131,588,705	87,818,229
Net loss per share attributable to Class A common stock:
Basic and diluted	$(0.12)	$(0.14)	$(0.38)	$(0.45)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.